GlobeNewsWire
16 Nov 2026, 07:00 UTC · 18h ago
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Impact · against what's priced in
Relmada Therapeutics is strengthening its clinical leadership to support the initiation of the Phase 3 SPECTRUM program for NDV-01. This move signals operational readiness for a key valuation catalyst before the 2027 readout.
- RMDN+0.60
No priced-in read yet





